Literature DB >> 8242225

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

V C Jordan1.   

Abstract

Tamoxifen has been found to be a safe and effective treatment for all stages of breast cancer. Long term tamoxifen therapy is associated with some rare, but potentially serious, side effects so patients should be carefully monitored. However, long term tamoxifen therapy is also associated with a number of physiological benefits over and above its tumouristatic action. These benefits include a decrease in the development of contralateral breast cancer, the maintenance of bone density in postmenopausal women and a decrease in cardiovascular disease. The successful application of tamoxifen to treat breast cancer has increased enthusiasm to test its worth to prevent breast cancer. Although there are individual requests by patients for tamoxifen to prevent breast cancer, individual treatment is inappropriate. Tamoxifen can only be adequately evaluated as a preventive in randomized, double-blind clinical trials. These trials are in place and physicians should encourage women to participate and establish a new therapeutic option as rapidly as possible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242225      PMCID: PMC2175926          DOI: 10.1111/j.1476-5381.1993.tb13840.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  131 in total

1.  Endometriosis developing during tamoxifen therapy.

Authors:  M R Ford; M J Turner; C Wood; W P Soutter
Journal:  Am J Obstet Gynecol       Date:  1988-05       Impact factor: 8.661

2.  Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

Authors:  M Andersson; H H Storm; H T Mouridsen
Journal:  J Natl Cancer Inst       Date:  1991-07-17       Impact factor: 13.506

3.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor.

Authors:  A B Schreiber; M E Winkler; R Derynck
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

4.  Tamoxifen as risk factor for carcinoma of corpus uteri.

Authors:  L Hardell
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

Review 5.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

6.  Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.

Authors:  B Fisher; A Brown; N Wolmark; C Redmond; D L Wickerham; J Wittliff; N Dimitrov; S Legault-Poisson; H Schipper; D Prager
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

7.  In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen.

Authors:  H T Huynh; E Tetenes; L Wallace; M Pollak
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

Review 8.  Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens.

Authors:  S Green
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

9.  Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report.

Authors:  D Gal; S Kopel; M Bashevkin; J Lebowicz; R Lev; M L Tancer
Journal:  Gynecol Oncol       Date:  1991-08       Impact factor: 5.482

10.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; G M Farrington; D Cosgrove; J B Davey; M Dowsett; J A McKinna; A G Nash; H D Sinnett
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

View more
  51 in total

1.  Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

Authors:  Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Renzo Wolbold; Andreas Nüssler; Peter Neuhaus; Ulrich M Zanger; Michel Eichelbaum; Thomas E Mürdter
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 2.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 3.  Systems approaches to molecular cancer diagnostics.

Authors:  Shuyi Ma; Cory C Funk; Nathan D Price
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

Review 4.  Targeted cancer therapy--are the days of systemic chemotherapy numbered?

Authors:  Won Duk Joo; Irene Visintin; Gil Mor
Journal:  Maturitas       Date:  2013-09-20       Impact factor: 4.342

5.  Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers.

Authors:  Shouping Liu; Weiwei Lai; Ying Shi; Na Liu; Lianlian Ouyang; Ziying Zhang; Ling Chen; Xiang Wang; Banglun Qian; Desheng Xiao; Qin Yan; Ya Cao; Shuang Liu; Yongguang Tao
Journal:  NPJ Precis Oncol       Date:  2020-03-03

6.  Genotoxicity of the some selective estrogen receptor modulators: a review.

Authors:  Serkan Yilmaz; Ilknur M Gönenç; Ebru Yilmaz
Journal:  Cytotechnology       Date:  2014-03-05       Impact factor: 2.058

7.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

8.  Alcohol-associated cancer and deregulation of Pol III genes.

Authors:  Ganggang Shi; Shuping Zhong
Journal:  Gene       Date:  2016-09-30       Impact factor: 3.688

9.  Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

Authors:  R A McClelland; D L Manning; J M Gee; E Anderson; R Clarke; A Howell; M Dowsett; J F Robertson; R W Blamey; A E Wakeling; R I Nicholson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Neural-Network Scoring Functions Identify Structurally Novel Estrogen-Receptor Ligands.

Authors:  Jacob D Durrant; Kathryn E Carlson; Teresa A Martin; Tavina L Offutt; Christopher G Mayne; John A Katzenellenbogen; Rommie E Amaro
Journal:  J Chem Inf Model       Date:  2015-09-04       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.